Gabapentin Dementia Lawsuit in Montana

Time limits apply in Montana. Find out if you still qualify.

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

People's Justice Research TeamUpdated June 11, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Statute of limitations — Montana

Montana: 3 years for personal injury (Mont. Code Ann. § 27-2-204). Discovery rule applies — limitations begin when the plaintiff discovers or should have discovered the injury and its cause.

3 years from discovery of injury

Filing venue

Where to File in Montana

Montana gabapentin cases are filed in the U.S. District Court for the District of Montana (Billings, Missoula, Great Falls, or Helena divisions) or in Montana district courts. Montana follows modified comparative negligence with a 50% bar. The state does not cap compensatory damages in product liability cases. Montana's vast geography means most cases are concentrated in Yellowstone County (Billings) and Missoula County courts.

Montana data

Exposure in Montana

Montana's annual gabapentin prescribing volume of approximately 450,000 prescriptions for 1.1 million residents reflects elevated per-capita usage driven by the state's physically demanding workforce and limited access to non-pharmaceutical pain management in remote communities.

~450,000 gabapentin Rx/year

Source: IQVIA / MT Board of Pharmacy data

Montana's population density of fewer than 8 people per square mile means many residents live hours from the nearest physician, let alone a neurologist. This extreme geographic isolation means gabapentin-induced cognitive decline is unlikely to be identified through routine care, and patients face significant barriers to obtaining diagnostic evaluations.

Remote healthcare access

Source: HRSA provider data / Montana DPHHS

Montana's significant Native American population faces compounded health disparities including elevated chronic pain rates, limited access to specialist care on reservations, and reduced healthcare infrastructure through Indian Health Service facilities. These factors may concentrate gabapentin exposure and cognitive risk in tribal communities.

Native American population risk

Source: Indian Health Service / Montana DPHHS

FAQ

Frequently Asked Questions

12 QUESTIONS

The evidence is now stronger than at any point in gabapentin's 30-year history. A July 2025 study published in Regional Anesthesia & Pain Medicine — one of the largest population-level analyses ever conducted on gabapentin's cognitive effects — found that patients who filled six or more gabapentin prescriptions had a 29% increased risk of developing dementia compared to matched controls. For patients aged 35 to 49, dementia risk doubled. The study also found an 85% increased risk of mild cognitive impairment, which is widely recognized as a precursor to dementia. Gabapentin works by binding to calcium channels in the brain that are essential for memory formation and learning. When those channels are chronically suppressed by daily gabapentin use, the result appears to be a gradual degradation of cognitive function that, in some patients, progresses to clinical dementia.

Gabapentin-related cognitive decline often begins subtly and is frequently attributed to stress, aging, or the underlying condition being treated. Early warning signs include increased forgetfulness — missing appointments, repeating questions, losing track of conversations. You or your family may notice difficulty with tasks that require planning or sequencing, like managing bills, following recipes, or navigating familiar routes. Word-finding problems — pausing mid-sentence to search for a common word — are another hallmark. Slower processing speed (taking longer to understand instructions or respond in conversation) and mental fog that doesn't clear with rest are also characteristic. The critical distinction from normal aging is the pace and severity of decline. If these symptoms developed or accelerated after starting gabapentin or after a dosage increase, the temporal relationship is significant and should be discussed with your doctor and documented for legal purposes.

First, you must have taken gabapentin (Neurontin or generic) chronically — generally six or more prescription fills or continuous use for a year or longer. Second, you must have developed documented cognitive symptoms: memory loss, confusion, difficulty concentrating, impaired executive function, or a formal diagnosis of mild cognitive impairment or dementia. Third, your cognitive decline must have occurred during or after your gabapentin use — temporal correlation is essential. Fourth, you should not have had a pre-existing neurodegenerative diagnosis (like Alzheimer's or Lewy body disease) before starting gabapentin. Pharmacy records documenting your gabapentin prescription history and medical records documenting your cognitive symptoms are the two most important pieces of evidence. A free case evaluation with a pharmaceutical injury attorney can help determine whether your specific circumstances support a claim.

The July 2025 study identified a clear dose-response relationship: the risk threshold was six or more gabapentin prescription fills. For a typical 30-day prescription, that translates to approximately six months of use — though many patients take gabapentin continuously for years. The study found that risk increased with cumulative exposure, meaning longer use correlated with higher dementia and MCI risk. Importantly, the study also showed that even within the six-prescription threshold group, younger patients (ages 35-49) faced dramatically elevated risk — suggesting that individual susceptibility varies and that no duration of chronic use should be considered categorically safe. Patients who took gabapentin at higher doses (1,800mg/day or above) for shorter periods may face comparable risk to those on lower doses for longer periods, as total cumulative brain exposure is the key variable.

As of early 2026, there is no certified class action for gabapentin-related cognitive decline. The litigation is in its emerging phase, with individual lawsuits being filed across multiple jurisdictions. Pharmaceutical injury attorneys are investigating claims and building the scientific and legal framework for what may become coordinated litigation — potentially through multi-district litigation (MDL) consolidation if sufficient cases are filed in federal court. Historically, major pharmaceutical injury litigations (Vioxx, Zantac, Roundup) began with individual filings before evolving into coordinated proceedings. The July 2025 study provides the foundational general causation evidence that is typically required before litigation achieves critical mass. Patients should not wait for a class action to be certified before consulting an attorney — statutes of limitations are running, and early filers often have the strongest cases.

Do not stop taking gabapentin abruptly. Sudden discontinuation of gabapentin can cause serious withdrawal symptoms including seizures — even in patients who were not taking the drug for epilepsy. Gabapentin must be tapered gradually under medical supervision, typically reducing the dose by no more than 25% per week. If you are concerned about cognitive effects, schedule an appointment with your prescribing physician to discuss your concerns, the July 2025 study findings, and a supervised tapering plan. Ask your doctor about alternative treatments for your underlying condition that have lower cognitive risk profiles. Simultaneously, request a formal cognitive assessment (neuropsychological evaluation) to establish a documented baseline of your current cognitive function — this serves both your medical care and your potential legal claim.

Statutes of limitations for pharmaceutical injury claims vary by state, typically ranging from one to six years. However, the critical question for gabapentin cases is when the clock starts running. Most states apply a 'discovery rule' — the limitations period begins when the patient knew or reasonably should have known that gabapentin caused their cognitive decline. For many patients, the July 2025 study represents the first time the gabapentin-dementia connection became publicly known, which may serve as the triggering discovery event. Tennessee has the shortest major-state SOL at one year, while states like Florida allow up to four years for product liability. Regardless of your state, the safest course is to consult an attorney as soon as possible — every month of delay increases the risk that a court will find you should have discovered the connection sooner.

Because this litigation is emerging, no specific gabapentin cognitive decline verdicts or settlements have been publicly reported. However, projections based on comparable pharmaceutical injury litigation suggest a wide range depending on the severity of cognitive impairment. Cases involving mild cognitive impairment with preserved daily function may fall in the $50,000 to $150,000 range. Early-onset dementia requiring some caregiver assistance could value between $200,000 and $500,000. Advanced dementia with total loss of independence may reach $400,000 to over $1 million. Wrongful death claims where gabapentin-associated cognitive decline contributed to death could exceed $2 million. Individual case value depends on age at diagnosis, documented gabapentin exposure history, severity of cognitive impairment, economic losses (lost income, care costs), and the strength of the causal connection established by medical experts.

Building a strong gabapentin cognitive decline claim requires two categories of evidence. First, you need complete documentation of your gabapentin exposure: pharmacy dispensing records showing every gabapentin prescription filled (date, dosage, quantity, refills), medical records showing the diagnosis for which gabapentin was prescribed, and any records of dosage changes or duration of continuous use. Most pharmacies maintain electronic records going back 10 or more years, and your insurance company or pharmacy benefit manager can provide claims history. Second, you need documentation of your cognitive decline: neuropsychological evaluation results, brain imaging (MRI), any formal diagnosis of MCI or dementia, and records from family members or employers documenting functional changes. The temporal relationship between gabapentin use and cognitive symptom onset is one of the strongest pieces of evidence your attorney can present.

The 2004 $430 million DOJ settlement resolved criminal charges related to Warner-Lambert's illegal off-label promotion of Neurontin — it did not resolve individual personal injury claims from patients harmed by the drug. The 2004 settlement is directly relevant to current litigation because it established, through Pfizer's own guilty plea, that gabapentin was systematically promoted for uses the FDA never approved and for which safety data was inadequate. If you were prescribed gabapentin for an off-label condition (pain, anxiety, insomnia, migraines, or other non-epilepsy, non-postherpetic neuralgia uses), the 2004 settlement strengthens the argument that you were exposed to gabapentin as a direct result of the company's illegal marketing practices. Your individual cognitive decline claim is separate from and not barred by the 2004 settlement.

Yes — the cognitive decline risk identified in the July 2025 study applies to gabapentin regardless of whether it was dispensed as brand-name Neurontin or a generic equivalent. Generic gabapentin contains the same active ingredient at the same dose and must meet the same FDA bioequivalence standards as the branded product. The neurotoxicity mechanism — chronic binding to alpha-2-delta calcium channel subunits in the brain — is a property of the gabapentin molecule itself, not of any particular manufacturer's formulation. The overwhelming majority of gabapentin prescriptions filled today are generic, as Neurontin's patent expired in 2004. For legal purposes, claims can be brought against both the original brand manufacturer (Pfizer) for failure to warn and inadequate labeling, and potentially against generic manufacturers under state consumer protection theories, depending on jurisdiction.

This was perhaps the most alarming finding of the July 2025 study. Adults aged 35 to 49 who used gabapentin chronically experienced a doubling of dementia risk and a tripling of MCI risk — the highest relative risk elevation of any age group studied. This is extraordinary because early-onset dementia in this age range is otherwise quite rare. The finding suggests that gabapentin may be triggering neurodegenerative processes in patients whose brains should be decades away from cognitive decline. Younger patients are often prescribed gabapentin for chronic pain conditions, fibromyalgia, anxiety, or migraines — all off-label uses that Pfizer's subsidiary was convicted of illegally promoting. If you are under 50 and experiencing memory problems, confusion, or cognitive difficulties while taking or after taking gabapentin, the July 2025 research suggests your age does not protect you — in fact, the data suggests younger chronic users face the steepest relative risk increase.

Keep reading

← Back to Gabapentin Dementia Lawsuit Lawsuit Overview Track the Gabapentin Dementia Lawsuit litigation timeline →

Quick Eligibility Review

Check your eligibility — free

Where to File in Montana

Exposure in Montana

Frequently Asked Questions

Can gabapentin cause dementia?

What are the signs of gabapentin-related cognitive decline?

Who qualifies for a gabapentin dementia lawsuit?

How long does gabapentin need to be taken before dementia risk increases?

Is there a gabapentin class action lawsuit?

Should I stop taking gabapentin if I'm worried about dementia?

What is the statute of limitations for gabapentin dementia claims?

How much are gabapentin dementia cases worth?

What evidence do I need for a gabapentin cognitive decline claim?

Does the 2004 Pfizer settlement affect my gabapentin dementia case?

Is generic gabapentin as risky as brand-name Neurontin?

Can younger adults develop early-onset dementia from gabapentin?